Back to List View Graph View

Anchusin

Anchusin is a biomedical entity categorized as a therapy-related target in the provided database context, and it appears to correspond to research on shikonin-based interventions.

Where the papers sit

10 papers from the last 6 months study anchusin directly · updated from PubMed 10 Nov 2026

Study type 0 clinical trials · 10 preclinical

Themes no clear themes

Those 10 do not share a common subject.

  • Shikonin is the common thread across delivery systems, inflammatory disease, cardiovascular injury, cancer, and plant biosynthesis. Reported mechanisms include ferroptosis, ferritinophagy, redox and mitochondrial regulation, immune modulation, and altered glycolipid metabolism. The studies also vary widely in endpoints, from brain delivery and chemotherapy enhancement to colitis, atherosclerosis, and myocardial fibrosis. No consistent therapeutic direction or shared clinical question emerges from this heterogeneous set.

    10 papers

anchusin chemical structure

Papers

The 10 papers from the last 6 months that study anchusin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

No clear themes (10)
  1. Quality by design-assisted development of an intranasal Shikonin-loaded Mucoadhesive microemulsion for enhanced brain delivery: optimization, characterization, and Pharmacodynamic evaluation in a schizophrenia model. Bioorganic chemistry · 1 Oct 2026 PMID 42822353
  2. Shikonin attenuates doxorubicin-induced myocardial senescence and fibrosis in association with improved redox and mitochondrial homeostasis. Molecular biology reports · 28 Sept 2026 PMID 42803853
  3. ROS-responsive bionanodrug for atherosclerosis therapy via regulating glycolipid metabolism and cell crosstalk. Journal of controlled release : official journal of the Controlled Release Society · 17 Sept 2026 PMID 42753822
  4. Single in situ intratumoral low‑dose shikonin hydrogel plus mild photothermal therapy elicits systemic antitumor immunity in immune‑cold triple‑negative breast cancer. International journal of oncology · 21 Aug 2026 PMID 42627061
  5. Selective Modulation of Th1-Mediated Inflammation and T Cell Metabolism via Shikonin-Loaded Nanogels. Immunology · 26 Jul 2026 PMID 42503000
  6. Drug library screening identifies colchicine and shikonin as therapeutic candidates for methotrexate-resistant choriocarcinoma. Biochemical and biophysical research communications · 20 Jul 2026 PMID 42476068
  7. A shikonin-based self-assembled nanomedicine alleviates DSS-induced colitis involving HDC-associated histamine regulation and gut microbiota modulation. Journal of materials chemistry. B · 16 Jun 2026 PMID 42300467
  8. Shikonin suppresses diffuse large B-cell lymphoma progression by inducing ferritinophagy and ferroptosis via lncRNA ADPGK-AS1 downregulation. Journal of enzyme inhibition and medicinal chemistry · 15 Jun 2026 PMID 42295078
  9. CRISPR/Cas9-mediated genome editing reveals the involvement of a polyphenol oxidase in the shikonin-specific biosynthesis in Lithospermum erythrorhizon. Plant & cell physiology · 29 May 2026 PMID 42213070
  10. Chemical proteomics identifies an autophagy receptor as a functional target of Shikonin in enhancing chemotherapy. Phytomedicine : international journal of phytotherapy and phytopharmacology · 22 May 2026 PMID 42172983

By study type

Preclinical: animal, cell and lab studies (10)
  1. Quality by design-assisted development of an intranasal Shikonin-loaded Mucoadhesive microemulsion for enhanced brain delivery: optimization, characterization, and Pharmacodynamic evaluation in a schizophrenia model. Bioorganic chemistry · 1 Oct 2026 PMID 42822353
  2. Shikonin attenuates doxorubicin-induced myocardial senescence and fibrosis in association with improved redox and mitochondrial homeostasis. Molecular biology reports · 28 Sept 2026 PMID 42803853
  3. ROS-responsive bionanodrug for atherosclerosis therapy via regulating glycolipid metabolism and cell crosstalk. Journal of controlled release : official journal of the Controlled Release Society · 17 Sept 2026 PMID 42753822
  4. Single in situ intratumoral low‑dose shikonin hydrogel plus mild photothermal therapy elicits systemic antitumor immunity in immune‑cold triple‑negative breast cancer. International journal of oncology · 21 Aug 2026 PMID 42627061
  5. Selective Modulation of Th1-Mediated Inflammation and T Cell Metabolism via Shikonin-Loaded Nanogels. Immunology · 26 Jul 2026 PMID 42503000
  6. Drug library screening identifies colchicine and shikonin as therapeutic candidates for methotrexate-resistant choriocarcinoma. Biochemical and biophysical research communications · 20 Jul 2026 PMID 42476068
  7. A shikonin-based self-assembled nanomedicine alleviates DSS-induced colitis involving HDC-associated histamine regulation and gut microbiota modulation. Journal of materials chemistry. B · 16 Jun 2026 PMID 42300467
  8. Shikonin suppresses diffuse large B-cell lymphoma progression by inducing ferritinophagy and ferroptosis via lncRNA ADPGK-AS1 downregulation. Journal of enzyme inhibition and medicinal chemistry · 15 Jun 2026 PMID 42295078
  9. CRISPR/Cas9-mediated genome editing reveals the involvement of a polyphenol oxidase in the shikonin-specific biosynthesis in Lithospermum erythrorhizon. Plant & cell physiology · 29 May 2026 PMID 42213070
  10. Chemical proteomics identifies an autophagy receptor as a functional target of Shikonin in enhancing chemotherapy. Phytomedicine : international journal of phytotherapy and phytopharmacology · 22 May 2026 PMID 42172983